triple agonist glp-1 Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care From GLP-1 to Triple Agonists:
Description
doi: 10.1002/jnr.v88:11 78 LieszASuri-PayerEVeltkampCDoerrHSommerCRivestSet al
Lancet Reg Health Eur
Supply chain limitations, cold-chain requirements, and healthcare provider familiarity further affect accessibility
Insulin resistance in type 1 diabetes: what is double diabetes and what are the risks
Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease
Some patients may require ongoing Semaglutide GLP-1 treatment to prevent weight regain, while others may transition to a reduced dosage or discontinue the medication altogether
